American Heart Journal

Slides:

Advertisements

Similar presentations

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Advertisements

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,

1 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation R3 Dae Ho Kim / Prof. Jin Bae Kim N Engl J Med 2011; DOI: Manesh R. Patel, M.D.,

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST) Kirsten E. Fleischmann,

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

To Anticoagulate or not to Anticoagulate

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Volume 149, Issue 6, Pages (June 2016)

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Heart, Lung and Circulation

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics Cheryl Bushnell,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population Richard K. Cheng, MD, MS,

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation Hany S. Abed, BPharm, MBBS, PhD,

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the.

Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention

Volume 28, Issue 6, Pages (December 2012)

Frontiers of anticoagulation therapy for atrial fibrillation

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA,

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Oral Anticoagulant Therapy

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

Access to NOAC Therapy:

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Oral Anticoagulant Therapy

Volume 137, Issue 2, Pages (February 2010)

A Clinical Study of COPD Severity Assessment by Primary Care Physicians and Their Patients Compared with Spirometry Douglas W. Mapel, MD, MPH, Anand.

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

Timing the First Postoperative Dose of Anticoagulants

Volume 145, Issue 1, Pages e15 (July 2013)

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Access to NOAC Therapy:

Adherence in SPAF: Measures to Improve Care

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Timing the First Postoperative Dose of Anticoagulants

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis Corey S. Miller,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction Sripal Bangalore, MD, MHA, Gregg.

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review Truman.

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban W. Frank Peacock, MD, CAPT Sally.

Barriers to colonoscopy among New York City homeless

Management of Difficult-to-Treat Atopic Dermatitis

Volume 16, Issue 1, Pages e3-e16 (January 2019)

Volume 14, Issue 12, Pages (December 2017)

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

Gavin C. Harewood, MD, FRCPI, MSc Gastrointestinal Endoscopy

Erratum Canadian Journal of Cardiology

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

A new oral anticoagulant in the setting of dermatologic surgery

Michelle C. Wallace, MD, James Jaggers, MD, Jennifer S

Presentation transcript:

American Heart Journal Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II) Benjamin A. Steinberg, MD, MHS, Peter Shrader, MA, Laine Thomas, PhD, Jack Ansell, MD, Gregg C. Fonarow, MD, Bernard J. Gersh, MB, ChB, DPhil, Elaine Hylek, MD, MPH, Peter R. Kowey, MD, Kenneth W. Mahaffey, MD, Emily C. O'Brien, PhD, Daniel E. Singer, MD, Eric D. Peterson, MD, MPH, Jonathan P. Piccini, MD, MHS American Heart Journal Volume 189, Pages 40-47 (July 2017) DOI: 10.1016/j.ahj.2017.03.024 Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 Use of NOAC versus warfarin in selected subgroups of patients with new-onset AF. *P<.05, **P<.0001. GIB, gastrointestinal bleeding; PCP, primary care physician; EP, electrophysiology. American Heart Journal 2017 189, 40-47DOI: (10.1016/j.ahj.2017.03.024) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 Histogram of individual oral anticoagulant use in patients with new-onset AF treated with any anticoagulation across sites for (A) warfarin, (B) dabigatran, (C) rivaroxaban, and (D) apixaban. American Heart Journal 2017 189, 40-47DOI: (10.1016/j.ahj.2017.03.024) Copyright © 2017 The Author(s) Terms and Conditions